Thr90Ser Mutation in Antithrombin is Associated with Recurrent Thrombosis in a Heterozygous Carrier

Abstract

Antithrombin (AT) is a serine protease inhibitor that regulates the activity of coagulation proteases of both intrinsic and extrinsic pathways. We identified an AT-deficient patient with a heterozygous Thr90Ser (T90S) mutation who experiences recurrent venous thrombosis. To understand the molecular basis of the clotting defect, we expressed AT-T90S in mammalian cells, purified it to homogeneity, and characterized its properties in established kinetics, binding, and coagulation assays. The possible effect of mutation on the AT structure was also evaluated by molecular modeling. Results demonstrate the inhibitory activity of AT-T90S toward thrombin and factor Xa has been impaired three- to fivefold in both the absence and presence of heparin. The affinity of heparin for AT-T90S has been decreased by four- to fivefold. Kinetic analysis revealed the stoichiometry of AT-T90S inhibition of both thrombin and factor Xa has been elevated by three- to fourfold in both the absence and presence of heparin, suggesting that the reactivity of coagulation proteases with AT-T90S has been elevated in the substrate pathway. The anticoagulant activity of AT-T90S has been significantly impaired as analyzed in the AT-deficient plasma supplemented with AT-T90S. The anti-inflammatory effect of AT-T90S was also decreased. Structural analysis predicts the shorter side-chain of Ser in AT-T90S has a destabilizing effect on the structure of AT and/or the AT-protease complex, possibly increasing the size of an internal cavity and altering a hydrogen-bonding network that modulates conformations of the allosterically linked heparin-binding site and reactive center loop of the serpin. This mutational effect increases the reactivity of AT-T90S with coagulation proteases in the substrate pathway.

Keywords

antithrombin - thrombosis - thrombin - factor Xa - stoichiometry

Authors' Contributions

L.Y. designed experiments and performed research; B.O.V. performed molecular modeling and contributed to writing of the related section; I.B. conducted the permeability assays; X.W. and Q.D. designed experiments, supervised studies conducted in Ruijin Hospital with the subjects' plasma; A.R.R. designed experiments, analyzed data, wrote the manuscript, and supervised the project. All authors approved the final version of this manuscript.

• References

• 1 Olson ST, Richard B, Izaguirre G, Schedin-Weiss S, Gettins PG. Molecular mechanisms of antithrombin-heparin regulation of blood clotting proteinases. A paradigm for understanding proteinase regulation by serpin family protein proteinase inhibitors. Biochimie 2010; 92 (11) 1587-1596
• 2 Gettins PG. Serpin structure, mechanism, and function. Chem Rev 2002; 102 (12) 4751-4804
• 3 Damus PS, Hicks M, Rosenberg RD. Anticoagulant action of heparin. Nature 1973; 246 (5432): 355-357
• 4 Carrell R, Skinner R, Jin L, Abrahams JP. Structural mobility of antithrombin and its modulation by heparin. Thromb Haemost 1997; 78 (01) 516-519
• 5 Schreuder HA, de Boer B, Dijkema R. , et al. The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions. Nat Struct Biol 1994; 1 (01) 48-54
• 6 Skinner R, Abrahams JP, Whisstock JC, Lesk AM, Carrell RW, Wardell MR. The 2.6 A structure of antithrombin indicates a conformational change at the heparin binding site. J Mol Biol 1997; 266 (03) 601-609
• 7 Huntington JA, McCoy A, Belzar KJ, Pei XY, Gettins PG, Carrell RW. The conformational activation of antithrombin. A 2.85-A structure of a fluorescein derivative reveals an electrostatic link between the hinge and heparin binding regions. J Biol Chem 2000; 275 (20) 15377-15383
• 8 Belzar KJ, Zhou A, Carrell RW, Gettins PG, Huntington JA. Helix D elongation and allosteric activation of antithrombin. J Biol Chem 2002; 277 (10) 8551-8558
• 9 Danielsson A, Raub E, Lindahl U, Björk I. Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa. J Biol Chem 1986; 261 (33) 15467-15473
• 10 Rezaie AR, Olson ST. Calcium enhances heparin catalysis of the antithrombin-factor Xa reaction by promoting the assembly of an intermediate heparin-antithrombin-factor Xa bridging complex. Demonstration by rapid kinetics studies. Biochemistry 2000; 39 (39) 12083-12090
• 11 Olson ST, Björk I, Sheffer R, Craig PA, Shore JD, Choay J. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem 1992; 267 (18) 12528-12538
• 12 Lane DA, Bayston T, Olds RJ. , et al; For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Antithrombin mutation database: 2nd (1997) update. Thromb Haemost 1997; 77 (01) 197-211
• 13 Perry DJ. Antithrombin and its inherited deficiencies. Blood Rev 1994; 8 (01) 37-55
• 14 Luxembourg B, Pavlova A, Geisen C. , et al. Impact of the type of SERPINC1 mutation and subtype of antithrombin deficiency on the thrombotic phenotype in hereditary antithrombin deficiency. Thromb Haemost 2014; 111 (02) 249-257
• 15 Rezaie AR, Yang L. Probing the molecular basis of factor Xa specificity by mutagenesis of the serpin, antithrombin. Biochim Biophys Acta 2001; 1528 (2-3): 167-176
• 16 Olson ST, Björk I, Shore JD. Kinetic characterization of heparin-catalyzed and uncatalyzed inhibition of blood coagulation proteinases by antithrombin. Methods Enzymol 1993; 222: 525-559
• 17 Dinarvand P, Yang L, Villoutreix BO, Rezaie AR. Expression and functional characterization of two natural heparin-binding site variants of antithrombin. J Thromb Haemost 2018; 16 (02) 330-341
• 18 Rezaie AR. Reactivities of the S2 and S3 subsite residues of thrombin with the native and heparin-induced conformers of antithrombin. Protein Sci 1998; 7 (02) 349-357
• 19 Zhou A, Huntington JA, Carrell RW. Formation of the antithrombin heterodimer in vivo and the onset of thrombosis. Blood 1999; 94 (10) 3388-3396
• 20 Lu Y, Mehta-D'souza P, Biswas I. , et al. Ile73Asn mutation in protein C introduces a new N-linked glycosylation site on the first EGF-domain of protein C and causes thrombosis. Haematologica 2019 . Doi: 10.3324/haematol.2019.227033
• 21 Johnson DJ, Langdown J, Li W, Luis SA, Baglin TP, Huntington JA. Crystal structure of monomeric native antithrombin reveals a novel reactive center loop conformation. J Biol Chem 2006; 281 (46) 35478-35486
• 22 Johnson DJ, Li W, Adams TE, Huntington JA. Antithrombin-S195A factor Xa-heparin structure reveals the allosteric mechanism of antithrombin activation. EMBO J 2006; 25 (09) 2029-2037
• 23 Jin L, Abrahams JP, Skinner R, Petitou M, Pike RN, Carrell RW. The anticoagulant activation of antithrombin by heparin. Proc Natl Acad Sci U S A 1997; 94 (26) 14683-14688
• 24 Ittisoponpisan S, Islam SA, Khanna T, Alhuzimi E, David A, Sternberg MJE. Can predicted protein 3D structures provide reliable insights into whether missense variants are disease associated?. J Mol Biol 2019; 431 (11) 2197-2212
• 25 Laskowski RA, Stephenson JD, Sillitoe I, Orengo CA, Thornton JM. VarSite: disease variants and protein structure. Protein Sci 2020; 29 (01) 111-119
• 26 Pires DE, Ascher DB, Blundell TL. DUET: a server for predicting effects of mutations on protein stability using an integrated computational approach. Nucleic Acids Res 2014; 42 (Web Server issue): W314-9
• 27 Getov I, Petukh M, Alexov E. SAAFEC: predicting the effect of single point mutations on protein folding free energy using a knowledge-modified MM/PBSA approach. Int J Mol Sci 2016; 17 (04) 512
• 28 Gyulkhandanyan A, Rezaie AR, Roumenina L. , et al. Analysis of protein missense alterations by combining sequence- and structure-based methods. Mol Genet Genomic Med 2020 . Doi: 10.1002/mgg3.1166
• 29 Bae JS, Rezaie AR. Mutagenesis studies toward understanding the intracellular signaling mechanism of antithrombin. J Thromb Haemost 2009; 7 (05) 803-810
• 30 dela Cruz RG, Jairajpuri MA, Bock SC. Disruption of a tight cluster surrounding tyrosine 131 in the native conformation of antithrombin III activates it for factor Xa inhibition. J Biol Chem 2006; 281 (42) 31668-31676
• 31 Lomas DA, Carrell RW. Serpinopathies and the conformational dementias. Nat Rev Genet 2002; 3 (10) 759-768
• 32 Xue M, Wakamoto T, Kejlberg C. , et al. How internal cavities destabilize a protein. Proc Natl Acad Sci U S A 2019; 116 (42) 21031-21036
• 33 Singh P, Jairajpuri MA. Strand 6B deformation and residues exposure towards N-terminal end of helix B during proteinase inhibition by serpins. Bioinformation 2011; 5 (08) 315-319
• 34 Lawrence DA, Olson ST, Muhammad S. , et al. Partitioning of serpin-proteinase reactions between stable inhibition and substrate cleavage is regulated by the rate of serpin reactive center loop insertion into beta-sheet A. J Biol Chem 2000; 275 (08) 5839-5844
• 35 Huntington JA, Read RJ, Carrell RW. Structure of a serpin-protease complex shows inhibition by deformation. Nature 2000; 407 (6806): 923-926
• 36 Strickland DK, Muratoglu SC, Antalis TM. Serpin-enzyme receptors LDL receptor-related protein 1. Methods Enzymol 2011; 499: 17-31
• 37 Águila S, Izaguirre G, Martínez-Martínez I, Vicente V, Olson ST, Corral J. Disease-causing mutations in the serpin antithrombin reveal a key domain critical for inhibiting protease activities. J Biol Chem 2017; 292 (40) 16513-16520
• 38 Meagher JL, Beechem JM, Olson ST, Gettins PG. Deconvolution of the fluorescence emission spectrum of human antithrombin and identification of the tryptophan residues that are responsive to heparin binding. J Biol Chem 1998; 273 (36) 23283-23289
• 39 Okajima K, Abe H, Maeda S. , et al. Antithrombin III Nagasaki (Ser116-Pro): a heterozygous variant with defective heparin binding associated with thrombosis. Blood 1993; 81 (05) 1300-1305